A 55-year-old man with established RA on etanercept + methotrexate presents with fever (38.5°C), productive cough, and bilateral lower lobe infiltrates on chest X-ray. He has no prior TB exposure documented. Sputum smear microscopy is negative for acid-fast bacilli. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient on TNF-α inhibitor therapy presents with: - Fever and respiratory symptoms - Radiological evidence of lower lobe infiltrates - Negative sputum smear (does NOT exclude TB) - Immunosuppression from biologic agent ## Risk of TB in TNF Inhibitor Therapy **High-Yield:** TNF-α inhibitors increase TB risk 15–25 fold, particularly reactivation of latent TB. Sputum smear negativity does NOT exclude TB — up to 50% of TB cases in immunosuppressed patients are smear-negative. **Key Point:** In any patient on TNF inhibitors presenting with respiratory symptoms and infiltrates, TB must be excluded before continuing the biologic agent. ## Diagnostic Algorithm | Investigation | Rationale | |---|---| | Sputum culture | Gold standard; takes 2–4 weeks but definitive | | GeneXpert MTB/RIF | WHO-recommended rapid molecular test; detects TB in 2 hours with high sensitivity/specificity | | Chest X-ray | Already done; shows infiltrates | | Sputum smear | Already negative; does NOT exclude TB | **Clinical Pearl:** GeneXpert MTB/RIF is now the first-line diagnostic test for TB in immunocompromised patients and has replaced sputum smear microscopy in most guidelines. It also detects rifampicin resistance, critical for treatment planning. ## Management Approach ```mermaid flowchart TD A[TNF inhibitor user with fever + infiltrates]:::outcome --> B[Sputum smear negative]:::outcome B --> C{TB excluded?}:::decision C -->|No| D[Hold TNF inhibitor]:::action D --> E[Sputum culture + GeneXpert MTB/RIF]:::action E --> F[Empiric broad-spectrum antibiotics]:::action F --> G{TB confirmed?}:::decision G -->|Yes| H[Start ATT, resume TNF inhibitor after 2 weeks]:::action G -->|No| H2[Continue antibiotics, restart TNF inhibitor]:::action C -->|Yes| I[Continue TNF inhibitor, treat bacterial infection]:::action ``` **Warning:** Continuing TNF inhibitors while TB is being ruled out risks severe disseminated TB. Conversely, unnecessary discontinuation of biologics in non-TB infections causes disease flare. The safe approach is to hold the agent pending rapid TB exclusion. **Mnemonic: STOP TB in TNF users** — **S**putum culture, **T**est with GeneXpert, **O**pportunistic infection screen, **P**ause TNF inhibitor; **T**reat empirically, **B**iologic restart after TB excluded.